deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT02665416

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody, Part I) or Bevacizumab (Anti-VEGF Monoclonal Antibody, Part II) in Patients With Metastatic Solid Tumors

Sponsor: Hoffmann-La Roche

Updated 22 times since 2017 Last updated: Apr 3, 2020 Started: Jan 25, 2016 Primary completion: Oct 30, 2019 Completion: Oct 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced/Metastatic Solid Tumors and is currently completed. Hoffmann-La Roche leads this study, which shows 22 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jul 2017 · 3 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Nov 2019 · 4 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

22 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. May 2020 — Jan 2021 [monthly]

    Completed PHASE1

Show 17 earlier versions
  1. Feb 2020 — May 2020 [monthly]

    Completed PHASE1

  2. Dec 2019 — Feb 2020 [monthly]

    Completed PHASE1

    Status: Active Not RecruitingCompleted

  3. Nov 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: RecruitingActive Not Recruiting

  4. Jul 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  5. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  6. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1

  7. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  8. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  9. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  10. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  11. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  12. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  13. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  14. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE1

  15. Apr 2017 — Jul 2017 [monthly]

    Recruiting PHASE1

  16. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

  17. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .